[go: up one dir, main page]

WO2010003009A3 - Induction synergique de l’immunité humorale et cellulaire par activation combinatoire de récepteurs de type toll - Google Patents

Induction synergique de l’immunité humorale et cellulaire par activation combinatoire de récepteurs de type toll Download PDF

Info

Publication number
WO2010003009A3
WO2010003009A3 PCT/US2009/049431 US2009049431W WO2010003009A3 WO 2010003009 A3 WO2010003009 A3 WO 2010003009A3 US 2009049431 W US2009049431 W US 2009049431W WO 2010003009 A3 WO2010003009 A3 WO 2010003009A3
Authority
WO
WIPO (PCT)
Prior art keywords
increase
cellular immunity
antigen
humoral
toll
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2009/049431
Other languages
English (en)
Other versions
WO2010003009A2 (fr
Inventor
Bali Pulendran
Sudhir Kasturi
Niren Murthy
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Emory University
Original Assignee
Emory University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Emory University filed Critical Emory University
Priority to US13/002,211 priority Critical patent/US20110104293A1/en
Priority to CA2729775A priority patent/CA2729775A1/fr
Priority to AU2009266940A priority patent/AU2009266940A1/en
Priority to EP09774459A priority patent/EP2303236A4/fr
Publication of WO2010003009A2 publication Critical patent/WO2010003009A2/fr
Publication of WO2010003009A3 publication Critical patent/WO2010003009A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/07—Bacillus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55516—Proteins; Peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5146—Organic macromolecular compounds; Dendrimers obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyamines, polyanhydrides
    • A61K9/5153—Polyesters, e.g. poly(lactide-co-glycolide)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Virology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Nanotechnology (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Medical Informatics (AREA)
  • Communicable Diseases (AREA)
  • Biophysics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

La présente invention concerne des compositions qui comprennent un antigène choisi, un ligand de TLR4 et un ligand de TLR7/TLR8, l’antigène et les ligands de TLR étant encapsulés dans des nanoparticules. La co-administration d’un ligand de TLR4 et d’un ligand de TLR7/TLR8 résulte en l’induction synergique de l’immunité humorale et cellulaire telle que mise en évidence par une augmentation de la production de cytokines pro-inflammatoires, une augmentation du nombre de cellules CD8+ T effectrices et T mémoires, une augmentation du titre d’anticorps spécifiques des antigènes, une augmentation de l’affinité des anticorps, une augmentation de la prolifération des cellules B naïves et/ou une amélioration significative de la persistance des anticorps et des réponses des cellules T. Les compositions et les procédés proposés par la présente invention peuvent être utilisés pour stimuler une réponse immunitaire telle qu’une réponse immunitaire à un agent pathogène ou à une tumeur.
PCT/US2009/049431 2008-07-01 2009-07-01 Induction synergique de l’immunité humorale et cellulaire par activation combinatoire de récepteurs de type toll Ceased WO2010003009A2 (fr)

Priority Applications (4)

Application Number Priority Date Filing Date Title
US13/002,211 US20110104293A1 (en) 2008-07-01 2009-07-01 Synergistic induction of humoral and cellular immunity by combinatorial activation of toll-like receptors
CA2729775A CA2729775A1 (fr) 2008-07-01 2009-07-01 Induction synergique de l'immunite humorale et cellulaire par activation combinatoire de recepteurs de type toll
AU2009266940A AU2009266940A1 (en) 2008-07-01 2009-07-01 Synergistic induction of humoral and cellular immunity by combinatorial activation of toll-like receptors
EP09774459A EP2303236A4 (fr) 2008-07-01 2009-07-01 Induction synergique de l immunité humorale et cellulaire par activation combinatoire de récepteurs de type toll

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US7741108P 2008-07-01 2008-07-01
US61/077,411 2008-07-01

Publications (2)

Publication Number Publication Date
WO2010003009A2 WO2010003009A2 (fr) 2010-01-07
WO2010003009A3 true WO2010003009A3 (fr) 2010-05-27

Family

ID=41466596

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2009/049431 Ceased WO2010003009A2 (fr) 2008-07-01 2009-07-01 Induction synergique de l’immunité humorale et cellulaire par activation combinatoire de récepteurs de type toll

Country Status (5)

Country Link
US (1) US20110104293A1 (fr)
EP (1) EP2303236A4 (fr)
AU (1) AU2009266940A1 (fr)
CA (1) CA2729775A1 (fr)
WO (1) WO2010003009A2 (fr)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010138194A2 (fr) 2009-05-27 2010-12-02 Selecta Biosciences, Inc. Composés agents immunomodulateurs-polymères
CN102844047B (zh) 2009-09-02 2017-04-05 诺华股份有限公司 含tlr活性调节剂的免疫原性组合物
US20110293700A1 (en) * 2010-05-26 2011-12-01 Selecta Biosciences, Inc. Nanocarrier compositions with uncoupled adjuvant
GB201009273D0 (en) * 2010-06-03 2010-07-21 Glaxosmithkline Biolog Sa Novel vaccine
CN105999275A (zh) 2010-09-01 2016-10-12 诺华有限公司 免疫增强剂吸附不溶性金属离子
US9994443B2 (en) 2010-11-05 2018-06-12 Selecta Biosciences, Inc. Modified nicotinic compounds and related methods
KR20140026392A (ko) 2011-03-02 2014-03-05 노파르티스 아게 저용량의 항원 및/또는 보조제를 갖는 조합 백신
BRPI1100857A2 (pt) * 2011-03-18 2013-05-21 Alexandre Eduardo Nowill agente imunomodulador e suas combinaÇÕes, seu uso e mÉtodo imunoterÁpico para a recontextualizaÇço, reprogramaÇço e reconduÇço do sistema imune em tempo real
WO2013019648A1 (fr) * 2011-07-29 2013-02-07 Selecta Biosciences, Inc. Contrôle des réponses d'anticorps envers des nanosupports synthétiques
US9375471B2 (en) 2012-03-08 2016-06-28 Glaxosmithkline Biologicals Sa Adjuvanted formulations of booster vaccines
WO2013163176A1 (fr) 2012-04-23 2013-10-31 Allertein Therapeutics, Llc Nanoparticules pour le traitement d'allergies
WO2014121132A1 (fr) * 2013-01-31 2014-08-07 The Oregon State Board Of Higher Education Acting By And Through Portland State University Compositions immunogènes comprenant un virus silicifié et procédés d'utilisation
ES2819234T3 (es) * 2013-02-25 2021-04-15 Particle Sciences Inc Formulaciones de partículas para la administración de agonistas de TLR y antígenos
CN105188741A (zh) 2013-04-03 2015-12-23 阿勒丁医疗公司 新型纳米颗粒组合物
KR101591927B1 (ko) 2013-04-29 2016-02-05 충남대학교 산학협력단 고분자 나노입자 기반의 암 백신 조성물
EP3302544A4 (fr) * 2015-05-26 2019-01-09 Ohio State Innovation Foundation Stratégie vaccinale à base de nanoparticules contre le virus de la grippe porcine
US11266746B2 (en) * 2016-06-27 2022-03-08 The United Slates of America, as represented by the Secretary, Department of Health and Human Services Therapeutic antitumor combination of a TLR4 ligand with other treatments
EP3579868A4 (fr) * 2017-02-13 2021-01-06 Nowill, Alexandre Eduardo Composition immunogène pour moduler le système immunitaire et procédés pour traiter des infections bactériennes chez un sujet
US20180296850A1 (en) * 2017-04-14 2018-10-18 Tianxin Wang Reagents and methods for cancer treatment using Magnetic particle
US11554178B2 (en) * 2017-06-30 2023-01-17 City Of Hope Compositions and methods of modulating macrophage activity
WO2019023622A1 (fr) * 2017-07-27 2019-01-31 The Board Of Trustees Of The Leland Stanford Junior University Nanoparticules polymères pourune immunothérapie anticancéreuse améliorée
AU2019389019A1 (en) 2018-11-26 2021-06-10 Duke University Compositions and methods for inducing scarring by peri-tumoral cells
RU2742580C2 (ru) * 2018-12-26 2021-02-08 федеральное государственное бюджетное учреждение «Национальный исследовательский центр эпидемиологии и микробиологии имени почетного академика Н.Ф. Гамалеи» Министерства здравоохранения Российской Федерации Фармацевтическая композиция на основе PLGA для индукции эффективного мукозального иммунного ответа
CN115252556A (zh) * 2022-08-02 2022-11-01 上海交通大学 糖基修饰的共负载蛋白和免疫激动剂的糖聚肽纳米囊泡及其应用
CN116270531A (zh) * 2023-04-20 2023-06-23 北京大学深圳医院（北京大学深圳临床医学院） 一种放疗增敏并激活远隔效应的中性粒细胞膜包裹纳米颗粒及其制备方法与应用

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030232074A1 (en) * 2002-04-04 2003-12-18 Coley Pharmaceutical Gmbh Immunostimulatory G, U-containing oligoribonucleotides
US20040091491A1 (en) * 2002-08-15 2004-05-13 3M Innovative Properties Company Immunostimulatory compositions and methods of stimulating an immune response
US20070087009A1 (en) * 2003-12-19 2007-04-19 Sanofi Pasteur Immunostimulant composition comprising at least one toll-like receptor 7 or toll-like receptor 8 agonist and a toll-like receptor 4 agonist

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030232074A1 (en) * 2002-04-04 2003-12-18 Coley Pharmaceutical Gmbh Immunostimulatory G, U-containing oligoribonucleotides
US20040091491A1 (en) * 2002-08-15 2004-05-13 3M Innovative Properties Company Immunostimulatory compositions and methods of stimulating an immune response
US20070087009A1 (en) * 2003-12-19 2007-04-19 Sanofi Pasteur Immunostimulant composition comprising at least one toll-like receptor 7 or toll-like receptor 8 agonist and a toll-like receptor 4 agonist

Also Published As

Publication number Publication date
US20110104293A1 (en) 2011-05-05
AU2009266940A1 (en) 2010-01-07
CA2729775A1 (fr) 2010-01-07
EP2303236A2 (fr) 2011-04-06
WO2010003009A2 (fr) 2010-01-07
EP2303236A4 (fr) 2012-09-26

Similar Documents

Publication Publication Date Title
WO2010003009A3 (fr) Induction synergique de l’immunité humorale et cellulaire par activation combinatoire de récepteurs de type toll
MX2025009673A (es) Composiciones para la terapia con celulas t con receptores de antigeno quimerico y usos de las mismas
MX2013013111A (es) Composicion inmunogenica que presenta antigeno multiple, y metodos y usos de la misma.
MX2013001527A (es) Nuevas vacunas adyuvantes en base a adyuvantes de orientacion para anticuerpos directamente hacia celulas presentadoras de antigenos.
EA201391610A1 (ru) Наноносители, вырабатывающие иммунную толерантность, для вырабатывания cd8+ регуляторных т-клеток
IN2015DN00138A (fr)
MX2009001412A (es) Vacunas de matriz de proteinas y metodos de hacer y administrar tales vacunas.
HK1256141A1 (zh) 表达嵌合抗原受体的修饰单核细胞/巨噬细胞及其用途
MX2014005372A (es) Molecula portadora que comprende un antigeno spr0096 y un spr2021.
MX2013011740A (es) Composiciones inmunogenicas y metodos para utilizar las composiciones para inducir respuestas inmunes humorales y celulares.
WO2014107652A3 (fr) Vaccins à forte densité en antigènes carbohydrates et comportant un adjuvant inédit à base de saponine
PH12014500666B1 (en) Cd27l antigen binding proteins
EP3508215A3 (fr) Amélioration de l'activité anticancéreuse de protéines de fusion fc immunomodulatrices
MY161724A (en) Therapeutic canine immunoglobulins and methods of using the same
TR200701350T1 (tr) Bazı aminoalkil glukozaminit fosfat bileşikleri ve bunların kullanımları
WO2021073659A3 (fr) Vecteur de vaccin préparé sur la base de polymères anioniques et dérivés de ceux-ci
WO2009133378A3 (fr) Produits et procédés permettant de stimuler une réponse immunitaire
WO2006063974A3 (fr) Jeux ordonnes d'antigenes il-15 et leurs utilisations
WO2014004385A3 (fr) Vaccins anticancéreux
WO2009149382A3 (fr) Anticorps anti-cd8 bloquant l’amorçage d’effecteurs cytotoxiques et conduisant à la génération de cellules t cd8<sp>+</sp> régulatrices
EP4337697A4 (fr) Compositions et méthodes se rapportant à des anticorps activés par des tumeurs ciblant egfr et des antigènes de cellules effectrices
WO2018094309A3 (fr) Traitement combiné fractal
WO2013019603A3 (fr) Cassettes d'expression linéaire et leurs utilisations
EP4297785A4 (fr) Compositions et méthodes comprenant des anticorps qui se lient à des conjugués peptidiques covalents
WO2015017113A3 (fr) Anticorps anti-tumoraux sélectifs, spécifiques de la protéine des récepteurs de la laminine immature de l'antigène oncofœtal

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 09774459

Country of ref document: EP

Kind code of ref document: A2

ENP Entry into the national phase

Ref document number: 2729775

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 13002211

Country of ref document: US

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2009266940

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2009774459

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2009266940

Country of ref document: AU

Date of ref document: 20090701

Kind code of ref document: A